Learn More -

FDA-Approved Mytesi Relieves Noninfectious Diarrhea in HIV-Positive Patients

By: EDGE Media Network

Yesterday, Napo Pharmaceuticals, Inc., announced the launch and general availability of Mytesi (crofelemer), the only antidiarrheal studied in and FDA-approved for the relief of diarrhea in HIV-positive patients. Previously marketed as Fulyzaq, the product launch under the Mytesi brand importantly includes the unveiling of the Mytesi Copay Savings Program and NapoCares™ Patient Assistance Program to provide people living with HIV/AIDS with broad, affordable access to the drug.

Read More

New drug treatment for relief of noninfectious diarrhea in HIV+ patients

By: Out In Jersey

Napo Pharmaceuticals announced the availability of Mytesi (crofelemer), the only antidiarrheal studied in and FDA-approved for the relief of diarrhea in HIV+ patients. Previously marketed as Fulyzaq, the product includes the unveiling of the Mytesi Copay Savings Program and NapoCares™ Patient Assistance Program to provide people living with HIV/AIDS with broad, affordable access to the drug

Read More
Optimization WordPress Plugins & Solutions by W3 EDGE